Medizone International Tightens Noose on Food-Borne Pathogens, Bed Bugs and MRSA

SAN FRANCISCO, Sept. 15, 2011 /PRNewswire/ -- Expanding on its already strong intellectual property protection program, Medizone International, Inc. (MZEI:OB MZEI:QB) has further strengthened its global position under the International Patent Cooperation Treaty.  Three refined versions of its US Provisional Applications covering the bed bug, food processing and sports equipment markets, have now been filed.

Medizone's President and Director of Medical Affairs, Dr Michael E. Shannon stated, "The filing of our Insect Infestation Control application reflects a major step forward for Medizone in its insect control program, particularly in the area of bedbug infestation – a world-wide problem which, until now, has been extremely difficult if not impossible to deal with.

"What's most exciting about our recent work is that by modifying our AsepticSure™ protocol, we also destroy larvae and eggs with a single treatment.

"Like the highly resistant spores of bacteria such as C difficile and Bacillus Subtilis, bedbug eggs are very difficult to kill and are often deposited in hard to reach areas. But with our new AsepticSure™ protocol, nothing survives! Hotel and motel rooms, homes, theaters, to mention only a few problem areas, can now be rid of a bedbug infestation in a single treatment with the additional benefit of having any bacterial pathogen simultaneously eliminated.

"Even when dealing with food borne pathogens, nothing can withstand our treatment process. Earlier this year, we announced that our AsepticSure™ system could effectively eliminate well-known pathogens such as Listeria, Salmonella and E coli from a vast array of contaminated surfaces, thereby offering an effective solution to yet another global challenge.

"Contaminated sports equipment will almost certainly become an issue of the past as our system is increasingly adopted by the athletic world. The list of potential applications is, in a word, huge – hence the requirement for new extended patent protection. These new patent applications must therefore be seen as part of an ever growing patent matrix reflecting the growing science of AsepticSure™."

CEO, Edwin Marshall pointed out, "Our technology's capability for the food processing industry has taken a giant leap forward in practicality. The charge time required for any given space to achieve sterilization is linear relative to the size of the space. Because we have now been able to achieve > 6 logs, 100% kill with food borne pathogens using dramatically lower charges of ozone than originally specified, the size of the area treatable with our equipment has expanded. This is commercially significant given the size of typical food processing facilities."

In closing Marshall added, "We have just received a 'Notice of Allowance' from the Canadian Patent Office for our foundational patent, 'Healthcare Facility Disinfecting Process and System with Oxygen/Ozone Mixture' and have taken the final, formal steps in the application process. It typically takes two to three months for the Granted patent to be issued following such steps. Medizone's patent protection program is not only on track, but the strength and expanse of the international reach has increased significantly and should greatly contribute to the value of AsepticSure™ moving forward."

For press information on Medizone, please contact:

Jack Eversull, Investor Relations, The Eversull Group, Inc.

T: 001-972-571-1624 F: 001-214-469-2361 E: [email protected]

Medizone International, Inc. is engaged in final production development of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures for building remediation. AsepticSure™ is also proving capable of the eradication of bed bug infestations.

This Press Release contains certain forward looking statements that may involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

For more information, visit: www.medizoneint.com

Email: [email protected]

SOURCE Medizone International, Inc.